Botulinum toxin: From life-threatening disease to novel medical therapy

American Journal of Obstetrics and Gynecology

Volumn 196, Issue 1, 2007, Pages 7-15

  Mahajan, Sangeeta T ^a   Brubaker, Linda ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

botox; botulinum toxin; detrusor overactivity incontinence; lower urinary tract dysfunction; urge incontinence

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDOTE; BOTULINUM TOXIN; BOTULINUM TOXIN A; CYCLOPHOSPHAMIDE; NEUROMUSCULAR BLOCKING AGENT; NEUROTOXIN; NEUROTRANSMITTER; PLACEBO;

BLEPHAROSPASM; BOTULISM; CERVICAL DYSTONIA; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; COMPARATIVE STUDY; DETRUSOR DYSSYNERGIA; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DYSTONIA; ELECTROMYOGRAPHY; ENVIRONMENTAL EXPOSURE; ESTHETICS; EUROPE; EXPERIMENTAL RAT; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART INFARCTION; HEREDITARY MOTOR SENSORY NEUROPATHY; HISTORY OF MEDICINE; HUMAN; HYPERHIDROSIS; LOWER URINARY TRACT SYMPTOM; MIGRAINE; MUSCLE DISEASE; MUSCLE SPASM; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; MYOFASCIAL PAIN; NAUSEA; NEUROMUSCULAR SYNAPSE; NEUROPHARMACOLOGY; NOMENCLATURE; NONHUMAN; PARESIS; PELVIS; PRIORITY JOURNAL; REVIEW; STRABISMUS; SUSPENSION; TORTICOLLIS; TREATMENT OUTCOME; UNITED STATES; URGE INCONTINENCE; URINE RETENTION; URODYNAMICS; VAGINISM; VOMITING; WRINKLE; XEROSTOMIA;

BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; BOTULISM; HUMANS; NEUROMUSCULAR AGENTS;

EID: 33846237720     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.03.108     Document Type: Review

References (67)

1. Ermengem E.V. Ueber einen neuen anaeroben Bacillus und seine Beziehungen zun Botulismus. Zeitschrift fur Hygiene und Infektionskrankheiten 26 (1897) 1-56
2. Dasgupta B. Structures of botulinum neurotoxin, its functional domains, and perspectives on the cristalline type A toxin. In: Jankovic M.H. (Ed). Therapy with botulinum toxin (1994), Marcel Dekker, Inc, New York
3. Davis L. Botulinum toxin: from poison to medicine. West J Med 158 (1995) 25-29
4. Scott A. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Opthalmol Soc 79 (1981) 734-770
5. Scott A., Rosenbaum A., and Collins C. Pharmacologic weakening of extraocular muscles. Opthalmol Vis Sci 12 (1973) 924-927
6. Schiavo G., Rossetto O., Santucci A., Dasgupta B., and Montecucco C. Botulinum neurotoxins are zinc proteins. J Biol Chem 267 (1992) 23479-23483
7. Simpson L., and Dasgupta B. Botulinum neurotoxin in type E: studies on the mechanism of action and on structure activity relationships. Pharmacol Exp Ther 224 (1983) 135-140
8. Simpson L. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 212 (1980) 16-21
9. Simpson L. Peripheral actions of the botulinum toxins. In: Simpson L. (Ed). Botulinum neurotoxin and tetanus toxin (1989), Academic Press, New York
10. Zhou L., Paiva Ad., Liu D., Aoki R., and Dolly J. Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP 25 and neurotoxicity after reconstitution with the heavy chain. Biochem 34 (1995) 15175-15181
11. Dolly J. General properties and cellular mechanisms of neurotoxins. In: Jankovic J., and Hallet M. (Eds). Therapy with botulinum toxin (1994), Marcel Dekker, New York
12. Dolly J., Black J., Williams R., and Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalisation. Nature 307 (1984) 457-460
13. Stecher B., Weller U., and Habermann E. The light chain but not the heavy chain of botulinum type A toxin inhibits exocytosis from permeabilised adrenal chromaffin cells. FEBS Lett 255 (1989) 318-325
14. Binder W., Brin M., Blitzer A., and Pogoda J. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis Mon 48 (2002) 323-335
15. Dykstra D., and Sidi A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin. Arch Phys Med Rehab 71 (1990) 24-26
16. Holds J., Alderson K., Fogg S., and Anderson R. Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest Opthalmol Vis Sci 31 (1990) 964-996
17. Maria G., Cassetta E., Gui D., Brisinda G., Bentivoglio A., and Albanese A. A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med 338 (1998) 217-220
18. Ansved T., and Odergren T. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology 48 (1997) 1440-1442
19. Leippold T., Reitz A., and Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44 (2003) 165-174
20. Emerson J. Botulinum toxin for spasmodic torticollis in a patient with myesthenia gravis. Mov Disord 9 (1994) 367
21. Greene P., and Fahn S. Development on antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: DasGupta B. (Ed). Boutlinum and tetanus neurotoxins: neurotransmission and biomedical aspects (1993), Plenum Press, New York
22. Greene P., Fahn S., and Diamond B. Development of resistance to botulinum toxi type A in patients with torticollis. Mov Disord 9 (1994) 213-217
23. Brin M. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 6 (1997) S146-S168
24. Gousse A., Tunuguntla H., Bateman D., and Velazquez A. Dose-finding prospective randomized study to evaluate the efficacy and safety of botulinum-A toxin for refractory non-neurogenic overactive bladder (2005) Presented at: American Urological Association Annual Meeting; San Antonio, TX.
25. Simpson D. Clinical trials of botulinum toxin in the treatment of spasticity. Muscle Nerve Suppl 6 (1997) S169-S175
26. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
27. Wein A. Neuromuscular dysfunction of the lower urinary tract and its management. In: Walsh P., Retik A., Vaughan E., and Wein A. (Eds). Campbell's urology Vol.2 (2002), WB Saunders, Philadelphia
28. Petit H., Wiart L., Gaujard E., et al. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36 (1998) 91-94
29. Dykstra D.D., Sidi A.A., Scott A.B., Pagel J.M., and Goldish G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139 (1988) 919-922
30. Schurch B., Stohrer M., Kramer G., Schmid D., Gaul G., and Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs?. Preliminary results. J Urol 164 (2000) 692-697
31. Reitz A., Stohrer M., Kramer G., et al. European experience of 200 cases treated with bolutlinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 (2004) 510-515
32. Schurch B., de Seze M., Denys P., et al. Botulinum toxin type A is a safe and effective treatment for neurogenic incontinence: results of a single treatment, randmized, placebo controlled 6-month study. J Urol 174 (2005) 196-200
33. Schmid D., Hebert A., Hauri D., and Schurch B. Experience of 100 cases treated with botulinum-A toxin injections into the detrusor muscle for overactive bladder refractory to anticholinergics (2005) Presented at: American Urologic Association; San Antonio, TX.
34. Sahai A., Khan M., Smith K., and Dasgupta P. Botulinum toxin-A for patients with idiopathic detrusor overactivity: early results from a randomized, double-blind, placebo-controlled trial (2005) Presented at: 35th Annual Meeting of the International Continence Society; Montreal, Canada.
35. Westney O., and McGuire E. Pubovaginal slings. In: Hurt W. (Ed). Urogynecologic surgery (2000), Lippincott, Williams & Wilkins, Baltimore
36. FitzGerald M., and Brubaker L. The etiology of urinary retention after surgery for genuine stress incontinence. Neurourol Urodyn 20 (2001) 12-21
37. Smith C., O'Leary M., Erickson J., Somogyi G., and Chancellor M. Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int J Urogyn 13 (2002) 55
38. Silberstein S., Mathew N., and Saper J. Botulinum toxin type A as a migraine preventative treatment. Headache 40 (2000) 445-450
39. Vemulakonda V., Smith C., Kiss S., Salas N.A., Boone T.B., and Smith C.P. Botulinum toxin A inhibits mechanorecptor-mediated urothelial release of ATP in conditions of bladder inflammation (2004) Presented at: American Urologic Association; San Francisco, CA.
40. Apostolidis A., Popat R., Yiangou Y., et al. Intra-detrusor botulinum toxin injections for human bladder overactivity decrease P2X3 but not PGP9.5 or ACHE expressing suburothelial innervation (2004) Presented at: American Urologic Association; San Francisco, CA.
41. Greene P., Kang U., Fahn S., Brin M., Moskowitz C., and Flaster E. Double-blind, placebo controlled trial of botulinum toxin injections for the treatment of spatic torticollis. Neurology 40 (1990) 1213-1218
42. Jankovic J., and Orman J. Botulinum A toxin for crainal-cervical dystonia; a double-blind placebo-controlled study. Neurology 37 (1987) 616-623
43. Ghazizadeh S., and Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Am J Obstet Gynecol 104 (2004) 922-925
44. Schurch B., Hauri D., Rodic B., Curt A., Meyer M., and Rossier A. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155 (1996) 1023-1029
45. Schurch B., Hodler J., and Rodic B. Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI contriolled transperineal injections. J Neurol Neurosurg Psychiatry 63 (1997) 474-476
46. Wheeler J., Walter J., Chintam R., and Rao S. Botulinum toxin injections for voiding dysfunction following SCI. J Spinal Cord Med 21 (1998) 227-229
47. Schulte-Baukloh H., Michael T., Schobert J., Stolze T., and Knispel H. Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59 (2002) 325-327
48. Loche A., Loche T., Osterhage J., Alloussi S., and Stockle M. Botulinum-A toxin detrsuor injections in the treatment of non-neurogenic and neurologic cases of urge incontinence. Eur Urol Suppl 2 (2003) 172
49. Radzieszewski P., and Borkowski A. Botulinum toxin type A intravesical injections for instable bladder overactivity. Eur Urol Suppl 1 (2002) 134
50. Yokoyama T., Kumon H., Smith C., Somogyi G.T., and Chancellor M.B. Botulinum toxin treatment of urethral and bladder dysfunction. Acta Med Okayama 56 (2002) 271-277
51. Abdelmalak J., Rackley R., Vasavada S., Ghoniem G., El-Azab A.S., and Moy L. Botluinum A toxin (Botox) injection for the treatment of refractory overactive bladder. J Pelvic Med Surg 10 (2004) S42-S43
52. Grosse J., Kramer G., and Stohrer M. Botulinum toxin A (BTX-A) injections for detrusor overactivity in patients with congenital spinal cord defects-first three years of experience (2004) Presented at: American Urologic Association; San Francisco, CA.
53. Corcos J., Taweel W.A., and Robichaud C. Botulinum-A toxin as an alternative treatment to bladder augmentation in children with neurogenic bladder due to myelomeningocele (2004) Presented at: American Urologic Association; San Francisco, CA.
54. Grosse J., Kramer G., and Stohrer M. Can videourodynamics predict the success of first and repeat multifocal botulinum toxin A (BTX-A) injections in severe neurogenic detrusor overactivity (NDO) (2004) Presented at: American Urologic Association; San Francisco, CA.
55. Kuo H. Urodynmic evidence of effectiveness of boutlinum A toxin injections in treatment of detrusor overactivty refractory to anticholinergic agents. Urology 63 (2004) 868-872
56. Gianhantoni A., Di Stasi S.M., Stephen R.L., et al. Intravesical resiniferatoxin versus botulinum-A toxin injections in patients with neurogenic detrusor overactivity: a prospective randomized trial. J Urol 172 (2004) 240-243
57. Grosse J., Kramer G., and Stohrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity incontinence. Eur Urol 47 (2005) 653-659
58. Smith C., Nishiguchi J., O'Leary M., Yoshimura N., and Chancellor M. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65 (2005) 37-41
59. Thoulouzan M., Soler J., Soulie M., et al. Prospective evaluation of botulinum toxin A (Botox) in neurogenic urinary incontinence (2005) Presented at: 35th Annual Meeting of the International Continence Society; Montreal, Canada.
60. Toh K., Tow A., and Consigliere D. Botolinum toxin type A for refractory detrusor overactivity in patients with spinal cord injuries in Asia: Preliminary results (2005) Presented at: 35th Annual Meeting of the International Continence Society, Montreal, Canada.
61. Karsenty G., Boy S., Reitz A., et al. Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)-A prospective randomized study to compare 30 vs. 10 injection sites (2005) Presented at: 35th Annual Meeting of the International Continence Society; Montreal, Canada.
62. Rapp D., Lucioni A., Katz E., O'Connor C., Gerber G., and Bales G. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63 (2004) 1071-1075
63. Werner M., Schmid D., and Schuessler B. Efficacy of botulinum-A toxin in the treatment of motor urge incontinence: a prospective non-randomized study. J Pelvic Med Surgery 10 (2004) S5
64. Flynn M., Webster G., and Amundsen C. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 172 (2004) 2316-2320
65. Werner M., Schmid D., and Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivty incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 192 (2005) 1735-1740
66. Rajkumar G., Small D., Mustafa A., and Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96 (2005) 848-852
67. Keppenne V., Gaspard Y., Mathantu B., Sanjurjo S., and Leval J.D. Detrusor injection of botulinum A toxin for idiopathic overactive bladder syndrome: clinical and urodynamic evaluation (2005) Presented at: 35th Annual Meeting of the International Continence Society; Montreal, Canada.